Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Edwards Lifesciences (EW) Stock Price & Analysis
1,689 Followers
EW Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$60.57 - $96.12
Previous Close$92.32
Volume1.52M
Average Volume (3M)2.81M
Market Cap
$55.63B
Enterprise Value$54.75B
Total Cash (Recent Filing)$1.64B
Total Debt (Recent Filing)$694.90M
Price to Earnings (P/E)39.7
Beta1.17
Next Earnings
Jul 24, 2024EPS Estimate
$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.33
Shares Outstanding602,600,000
10 Day Avg. Volume2,917,839
30 Day Avg. Volume2,810,018
Standard Deviation0.09
R-Squared0.43
Alpha-0.00271
Financial Highlights & Ratios
Price to Book (P/B)11.03
Price to Sales (P/S)9.12
Price to Cash Flow (P/CF)100.30
P/FCF Ratio172.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.12
Enterprise Value/Gross Profit11.84
Enterprise Value/Ebitda33.55
Forecast
1Y Price Target
$98.50Price Target Upside6.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Edwards Lifesciences News
PremiumCompany Announcements
Edwards Lifesciences Announces Senior Financial Leadership Transition
PremiumCompany Announcements
Edwards Lifesciences Announces Major Divestiture and Deal Cautions
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe $4.2 billion cash injection is likely to fund many internal investment projects, which could be crucial in supporting indication expansion initiatives to asymptomatic and less severe patients over the next few years.
Growth PotentialThe pipeline can drive sustainable double-digit revenue growth.
Product InnovationEnrollment in the phase 2 cohort was much faster than anticipated, resulting in EVOQUE approval 6-12 months ahead of schedule.
Bears Say
EarningsThe deal is likely to be EPS dilutive for EW in 2025.
Market PerformanceMarket share erosion expected for EW based on survey respondents.
Product PerformanceSmart trial reported a 20% paravalvular leak rate for Sapien 3, which is higher than the 10-12% rates observed in real-world registries such as the TVT registry.
---
Ownership Overview
1.09% Insiders
23.63% Mutual Funds
19.83% Other Institutional Investors
55.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $60.57 and its highest was $96.12 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 24, 2024 which is in 17 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 25, 2024. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.643 by $0.017.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is $0.69.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 602,600,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.66 in its last earnings report, beating expectations of $0.643. Following the earnings report the stock price went down -1.795%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 729M.
---
Edwards Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$98.50 (6.69% Upside)
$98.50 (6.69% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 50.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $49.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.49%
12-Months-Change
Fundamentals
Return on Equity
21.59%
Trailing 12-Months
Asset Growth
12.54%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EW Earnings Call
Q1 2024
0:00 / 0:00
---
EW Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$98.50
▲(6.69% Upside)
Technical Analysis
Best Analysts Covering EW
1 Year
1 Year Success Rate
24/31 ratings generated profit
1 Year Average Return
+14.28%
reiterated a buy rating last month
Copying Matt Miksic's trades and holding each position for 1 Year would result in 77.42% of your transactions generating a profit, with an average return of +14.28% per trade.
---